Carregant...
Neither T-helper type 2 nor Foxp3(+) regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity
Oral atorvastatin has prevented or reversed paralysis in the multiple sclerosis (MS) model experimental autoimmune encephalomyelitis (EAE), and reduced development of new MS lesions in clinical trials. Besides inhibiting development of encephalitogenic T cells, atorvastatin treatment of EAE has been...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3922392/ https://ncbi.nlm.nih.gov/pubmed/24498870 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-2094-11-29 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|